← Back
Data updated: Jun 28, 2026
AVADEL CNS
Pharma Pharmaceuticals
AVADEL CNS is a pharmaceutical company with 1 FDA-approved products.
2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
AVADEL CNS's Key Drugs
AVADEL CNS's core commercial portfolio centers on LUMRYZ — its most strategically important drugs approved in the last 15 years.
AVADEL CNS's Recent FDA Approvals
New NDA/BLA approvals for AVADEL CNS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
AVADEL CNS's Therapeutic Areas
Disease areas where AVADEL CNS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
AVADEL CNS Pipeline Snapshot
Active clinical trials for AVADEL CNS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LUMRYZ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-05-01
- Latest
- 2025-03-10
- Applications
- 1